* If you want to update the article please login/register
We looked at the effects of intra-articular sprifermin, a recombinant fibroblast growth factor 18, on cartilage healing at the site of injury in the present study. We created a cartilage defect and performed microfracture surgery in 18 horses' fetlock joints, treated joints with one of three doses of sprifermin or with saline, hyaluronan, and assessed animals' clinical and structural outcomes over 24 weeks. In three regions of concern, we undertook histological and gene expression analysis of aggrecan, collagen types I and II, and cartilage oligomeric matrix protein in primary outcome measures. Following 100 g sprifermin therapy, we observed the greatest treatment benefit. For the first time, our findings revealed an improvement in microfracture outcomes following sprifermin therapy, suggesting a cartilage regenerative role and a potential benefit of sprifermin therapy in early cartilage injuries.
Source link: https://doi.org/10.1002/jor.25063
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions